Moat Ross 4

4 · Kiniksa Pharmaceuticals International, plc · Filed May 5, 2025

Insider Transaction Report

Form 4

Period: 2025-05-01

Kiniksa Pharmaceuticals International, plcKNSA

Moat Ross

CHIEF COMMERCIAL OFFICER

Transactions

Award
Performance Share Unit
2025-05-01+4,976→ 4,976 total
→ Class A Ordinary Share (4,976 underlying)
Award
Performance Share Option
2025-05-01+8,303→ 8,303 total
Exercise: $27.74Exp: 2035-04-30→ Class A Ordinary Share (8,303 underlying)
Sale
Class A Ordinary Share
2025-05-05$28.00/sh−6,272$175,616→ 9,415 total
Exercise/Conversion
Class A Ordinary Share
2025-05-02$17.76/sh+3,850$68,376→ 13,265 total
Exercise/Conversion
Class A Ordinary Share
2025-05-05$17.76/sh+6,272$111,391→ 15,687 total
Award
Performance Share Unit
2025-05-01+5,225→ 5,225 total
→ Class A Ordinary Share (5,225 underlying)
Sale
Class A Ordinary Share
2025-05-02$28.00/sh−3,850$107,800→ 9,415 total
Exercise/Conversion
Share Option
2025-05-02−3,850→ 33,661 total
Exercise: $17.76Exp: 2033-08-31→ Class A Ordinary Share (3,850 underlying)
Exercise/Conversion
Share Option
2025-05-05−6,272→ 27,389 total
Exercise: $17.76Exp: 2033-08-31→ Class A Ordinary Share (6,272 underlying)
Award
Performance Share Option
2025-05-01+8,043→ 8,043 total
Exercise: $27.74Exp: 2035-04-30→ Class A Ordinary Share (8,043 underlying)

Footnotes (10)

[F1]This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.
[F10]The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
[F2]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F3]This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
[F4]Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.
[F5]The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.
[F6]The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
[F7]The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.
[F8]The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.
[F9]The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Documents

1 file

4
form4-05052025_080547.xmlPrimary